Name: Azetukalner (XEN1101) in Focal onset seizures: Co-prescribed/Concomitant therapies
Published: 2026-09-21T21:41:53-04:00

Product information and disease description Product description Product information

Co-prescribed/Concomitant therapies

5 evidence topics · 5 sources

Adjunctive use on a background of one to three antiseizure medications

“Treatment with a stable dose of 1 to 3 allowable current ASMs for at least one month prior to screening, during baseline, and throughout the duration of the DBP” (opens the source at this quote in a new tab)

Concomitant antiseizure medication use in the Phase 3 trial population

“Participants had highly treatment-resistant epilepsy, with a median of five prior ASMs, a baseline seizure frequency of 12.75 per month, and 51.3% using three concomitant ASMs.” (opens the source at this quote in a new tab)

Concomitant antiseizure medication use in the Phase 2b trial population

“A total of 8.9% of the patients received 1 stable ASM at baseline and concomitantly throughout the DBP of the study, 40.6% of the patients received 2, and 50.5% of the patients received 3. Patients had tried and stopped a median of 6 previous ASMs before study entry. More than half of the patients (57.8%) were taking a CYP3A4 inducer at baseline.” (opens the source at this quote in a new tab)

Polytherapy in routine epilepsy management

“Epilepsy is often managed with polytherapy – or concurrent use of multiple antiseizure medications (ASMs) – to improve seizure control. However, despite more than 30 available epilepsy treatments, up to half of people with focal epilepsy still live with uncontrolled seizures.” (opens the source at this quote in a new tab)

Rationale for combining distinct mechanisms of action

“Currently, healthcare professionals only have a handful of MOAs to choose from when treating epilepsy, and patients who do not respond to or tolerate an ASM with a specific MOA may be less likely to benefit from others with a similar MOA. Therefore, it is imperative that different MOAs be introduced to the treatment armamentarium to give more people living with epilepsy the opportunity to achieve seizure control.” (opens the source at this quote in a new tab)